뇌졸중 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Stroke Market is expected to grow at a CAGR of 7.4% from a market value of USD 47.2 billion in 2026 to USD 89.9 billion in 2035.

Growing investments in comprehensive stroke centers, artificial intelligence-assisted imaging, and next-generation thrombolytic therapies are transforming stroke management while creating significant commercial opportunities across pharmaceutical, biotechnology, and medical device industries.

Stroke is one of the leading causes of death and long-term disability worldwide and remains a major public health challenge. The disease includes ischemic stroke, hemorrhagic stroke, and transient ischemic attack (TIA), with ischemic stroke accounting for the majority of cases. Rapid diagnosis and timely intervention remain essential for improving patient outcomes, driving continued investment in innovative therapeutics, endovascular procedures, and integrated stroke care networks.

Market Drivers

Rising Global Stroke Burden

The growing incidence of stroke associated with aging populations and increasing cardiovascular risk factors continues to expand demand for acute treatment, secondary prevention, and long-term rehabilitation services. Hypertension, diabetes, obesity, dyslipidemia, smoking, and atrial fibrillation remain the primary contributors to rising stroke incidence worldwide.

Expansion of Mechanical Thrombectomy

Mechanical thrombectomy has become a standard treatment for eligible patients with large-vessel occlusion ischemic stroke. Increasing adoption of endovascular therapy, supported by expanding comprehensive stroke centers and improved physician expertise, continues to drive market growth.

Growing Adoption of Next-Generation Thrombolytics

Clinical guidelines increasingly support simplified thrombolytic therapies such as tenecteplase because of their ease of administration and favorable workflow efficiency. Continued regulatory support and physician adoption are strengthening demand for innovative thrombolytic agents.

Expansion of Stroke Care Infrastructure

Healthcare systems worldwide are investing in comprehensive stroke centers, emergency stroke networks, tele-stroke programs, and rapid diagnostic capabilities to reduce treatment delays and improve clinical outcomes.

Market Restraints

Limited Treatment Window

The effectiveness of thrombolytic therapy declines rapidly after symptom onset, limiting the proportion of patients eligible for acute intervention.

Risk of Intracranial Hemorrhage

The potential for serious bleeding complications continues to limit broader utilization of thrombolytic therapies and requires careful patient selection.

Limited Access to Advanced Stroke Centers

Many developing regions continue to experience shortages of specialized stroke centers, neurointerventional specialists, and advanced imaging infrastructure, restricting access to optimal stroke care.

Market and Technology Insights

The global stroke market can be segmented by drug type, indication, treatment type, end user, and geography.

By drug type, the market includes thrombolytics, antiplatelet agents, anticoagulants, and other supportive therapies. Thrombolytics remain central to acute ischemic stroke treatment, while antiplatelet and anticoagulant therapies play a critical role in long-term secondary prevention.

By indication, the market comprises ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke accounts for the largest market share because it represents the majority of stroke cases and has well-established pharmacological and interventional treatment options.

By treatment type, the market includes intravenous medication, endovascular therapy, surgical procedures including mechanical thrombectomy and carotid endarterectomy, and rehabilitation services. Endovascular therapy continues to experience rapid growth because of expanding evidence supporting improved functional outcomes in eligible patients.

By end user, the market covers hospitals, specialty stroke centers, rehabilitation centers, and other healthcare facilities. Comprehensive stroke centers remain the primary providers of advanced stroke diagnosis and treatment.

Technological innovations including artificial intelligence-assisted imaging, automated stroke triage, tele-stroke networks, advanced neuroimaging, digital health platforms, and robotic-assisted neurointerventional procedures are improving diagnostic accuracy, reducing treatment delays, and enhancing patient outcomes.

Market Trends

The global stroke market continues to evolve through advances in acute intervention and precision stroke care.

Key market trends include:

• Increasing adoption of mechanical thrombectomy.
• Expansion of tenecteplase and next-generation thrombolytic therapies.
• Growing implementation of AI-assisted stroke imaging.
• Expansion of comprehensive stroke centers.
• Greater emphasis on rapid diagnosis and treatment pathways.
• Increasing investment in neuroprotective therapies.
• Strengthening secondary prevention through personalized cardiovascular risk management.

Regional Insights

North America remains the largest stroke market because of advanced healthcare infrastructure, comprehensive stroke networks, favorable reimbursement systems, and strong adoption of innovative therapeutics and interventional procedures. The region also leads global clinical research and commercialization activities.

Europe continues to maintain a significant market share through established stroke treatment pathways, structured reimbursement systems, and widespread implementation of evidence-based clinical guidelines.

Asia-Pacific is expected to witness the fastest market growth owing to rapid population aging, increasing stroke incidence, expanding healthcare infrastructure, improving emergency stroke care, and growing healthcare investment across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening stroke care through healthcare modernization, improved referral systems, and increasing investment in specialized stroke treatment facilities.

Competitive Landscape

The global stroke market includes multinational pharmaceutical companies, biotechnology firms, medical device manufacturers, diagnostic imaging companies, and digital health providers.

Market participants continue investing in next-generation thrombolytics, neuroprotective therapies, artificial intelligence-enabled imaging, mechanical thrombectomy technologies, precision medicine, and integrated stroke care platforms. Strategic collaborations, licensing agreements, mergers and acquisitions, and geographic expansion remain key competitive strategies supporting long-term market growth.

Future Outlook

The future of the stroke market is expected to be driven by continued advances in acute stroke treatment, artificial intelligence, neuroprotection, precision medicine, and digital healthcare. Broader implementation of comprehensive stroke systems of care, AI-assisted imaging, wearable monitoring technologies, and personalized secondary prevention strategies is expected to improve patient outcomes while expanding commercial opportunities.

Continued research into neuroprotective agents, regenerative medicine, and advanced endovascular technologies is expected to further transform stroke management throughout the forecast period.

Conclusion

The global Stroke Market is expected to experience sustained growth through 2035, supported by increasing stroke incidence, expanding adoption of advanced reperfusion therapies, growing investment in stroke care infrastructure, and continuous innovation in pharmaceuticals and medical technologies. Although challenges related to treatment timing, access to specialized care, and safety considerations remain, ongoing advances in artificial intelligence, neurointervention, and precision medicine are expected to improve patient outcomes and create significant opportunities for healthcare providers, pharmaceutical companies, medical device manufacturers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global stroke market and future growth opportunities.
• Detailed evaluation of market drivers, restraints, treatment innovations, and technology trends.
• Competitive assessment of leading companies, strategic developments, and commercialization activities.
• Insights into regional market dynamics, regulatory developments, and future investment opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, portfolio optimization, investment analysis, licensing and partnership evaluation, commercialization planning, regulatory strategy development, market entry assessment, and identification of emerging business opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke market by drug type, indication, treatment type, end user, and geography
• Evaluation of market size, growth drivers, restraints, competitive landscape, and emerging treatment trends
• Assessment of regulatory frameworks, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
• Analysis of thrombolytics, antiplatelet agents, anticoagulants, endovascular therapies, artificial intelligence-enabled diagnostics, neuroprotective therapies, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Overview
• 1.2 Key Findings
• 1.3 Stroke Market Snapshot
• 1.4 Key Epidemiology Insights
• 1.5 Key Commercialized Therapies Overview
• 1.6 Pipeline Development Highlights
• 1.7 Market Size and Forecast Summary (2025-2035)
• 1.8 Key Growth Opportunities
• 1.9 Strategic Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Stroke
  • 2.1.1 Definition and Clinical Overview
  • 2.1.2 Disease Burden and Public Health Impact
  • 2.1.3 Stroke Classification
• 2.2 Stroke Pathophysiology
  • 2.2.1 Ischemic Stroke
  • 2.2.2 Hemorrhagic Stroke
  • 2.2.3 Transient Ischemic Attack (TIA)
• 2.3 Risk Factors and Disease Etiology
  • 2.3.1 Hypertension
  • 2.3.2 Atrial Fibrillation
  • 2.3.3 Diabetes Mellitus
  • 2.3.4 Dyslipidemia
  • 2.3.5 Obesity
  • 2.3.6 Smoking and Alcohol Consumption
  • 2.3.7 Aging Population
• 2.4 Epidemiology Analysis
  • 2.4.1 Global Prevalence
  • 2.4.2 Global Incidence
  • 2.4.3 Mortality Analysis
  • 2.4.4 Disability Burden Analysis
  • 2.4.5 Recurrent Stroke Population
• 2.5 Epidemiology by Stroke Type
  • 2.5.1 Ischemic Stroke
  • 2.5.2 Intracerebral Hemorrhage
  • 2.5.3 Subarachnoid Hemorrhage
  • 2.5.4 Transient Ischemic Attack
• 2.6 Epidemiology by Demographics
  • 2.6.1 Age-Based Analysis
  • 2.6.2 Gender-Based Analysis
  • 2.6.3 High-Risk Population Analysis
• 2.7 Epidemiology Forecast (2025-2035)

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Global Stroke Burden
  • 3.1.2 Growing Aging Population
  • 3.1.3 Increasing Awareness and Early Diagnosis
  • 3.1.4 Expanding Access to Acute Stroke Care
  • 3.1.5 Advancements in Reperfusion Therapies
  • 3.1.6 Increasing Secondary Prevention Adoption
• 3.2 Market Restraints
  • 3.2.1 Narrow Therapeutic Time Windows
  • 3.2.2 Treatment Accessibility Challenges
  • 3.2.3 High Healthcare Costs
  • 3.2.4 Limited Neuroprotective Treatment Options
• 3.3 Market Opportunities
  • 3.3.1 Neuroprotective Drug Development
  • 3.3.2 Regenerative Medicine Approaches
  • 3.3.3 AI-Enabled Stroke Management
  • 3.3.4 Emerging Market Expansion
• 3.4 Market Challenges
  • 3.4.1 Delayed Patient Presentation
  • 3.4.2 Post-Stroke Disability Burden
  • 3.4.3 Reimbursement Constraints
  • 3.4.4 Clinical Trial Complexity
• 3.5 Porter's Five Forces Analysis
• 3.6 PESTLE Analysis
• 3.7 Value Chain Analysis
• 3.8 Unmet Needs Assessment

4. Commercial & Market Access

• 4.1 Market Access Overview
• 4.2 Reimbursement Landscape
• 4.3 Health Technology Assessment Trends
• 4.4 Pricing Analysis
• 4.5 Patient Access Programs
• 4.6 Payer Perspectives
• 4.7 Market Access Challenges
• 4.8 Market Access Opportunities

5. Innovation & Pipeline Landscape

• 5.1 Pipeline Overview
• 5.2 Pipeline Analysis by Development Stage
  • 5.2.1 Discovery and Preclinical
  • 5.2.2 Phase I
  • 5.2.3 Phase II
  • 5.2.4 Phase III
• 5.3 Pipeline Analysis by Modality
  • 5.3.1 Small Molecules
  • 5.3.2 Biologics
  • 5.3.3 Cell Therapies
  • 5.3.4 Gene Therapies
  • 5.3.5 Combination Therapies
• 5.4 Pipeline Analysis by Mechanism of Action
  • 5.4.1 Neuroprotection
  • 5.4.2 Thrombolysis Enhancement
  • 5.4.3 Anti-Inflammatory Mechanisms
  • 5.4.4 Neuroregeneration
  • 5.4.5 Stem Cell-Based Approaches
• 5.5 Clinical Trial Landscape
  • 5.5.1 Ongoing Phase I Trials
  • 5.5.2 Ongoing Phase II Trials
  • 5.5.3 Ongoing Phase III Trials
  • 5.5.4 Trial Distribution by Geography
  • 5.5.5 Trial Distribution by Sponsor Type
• 5.6 Emerging Technologies
  • 5.6.1 Biomarker-Based Patient Selection
  • 5.6.2 AI-Driven Stroke Management
  • 5.6.3 Digital Therapeutics
  • 5.6.4 Precision Medicine Approaches
• 5.7 Licensing, Collaboration, and Partnership Activity
• 5.8 Mergers and Acquisitions Analysis

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Stroke Management
  • 6.2.1 Intravenous Thrombolysis
  • 6.2.2 Mechanical Thrombectomy
  • 6.2.3 Neurocritical Care
• 6.3 Secondary Stroke Prevention
  • 6.3.1 Antiplatelet Therapy
  • 6.3.2 Anticoagulant Therapy
  • 6.3.3 Lipid-Lowering Therapy
  • 6.3.4 Blood Pressure Management
• 6.4 Commercialized Drug Landscape
  • 6.4.1 Alteplase (Activase)
  • 6.4.2 Tenecteplase
  • 6.4.3 Aspirin
  • 6.4.4 Clopidogrel
  • 6.4.5 Ticagrelor (Brilinta)
  • 6.4.6 Rivaroxaban (Xarelto)
  • 6.4.7 Apixaban (Eliquis)
  • 6.4.8 Dabigatran (Pradaxa)
  • 6.4.9 Edoxaban (Lixiana/Savaysa)
• 6.5 Stroke Rehabilitation Landscape
  • 6.5.1 Physical Rehabilitation
  • 6.5.2 Occupational Therapy
  • 6.5.3 Speech Therapy
  • 6.5.4 Digital Rehabilitation Solutions
• 6.6 Treatment Algorithm by Stroke Type

7. Global Stroke Market Forecast Report Size & Forecast (2025-2035)

• 7.1 Global Market Overview
• 7.2 Historical Market Analysis (2020-2024)
• 7.3 Forecast Assumptions
• 7.4 Global Market Forecast (2025-2035)
• 7.5 Market Forecast by Treatment Type
• 7.6 Market Forecast by Indication
• 7.7 Market Forecast by Route of Administration
• 7.8 Market Forecast by End User
• 7.9 Opportunity Assessment

8. Global Stroke Market Forecast Report Segmentation

• 8.1 By Stroke Type
  • 8.1.1 Ischemic Stroke
    • 8.1.1.1. Thrombotic
    • 8.1.1.2. Embolic
  • 8.1.2 Hemorrhagic Stroke
  • 8.1.3 Transient Ischemic Attack
  • 8.1.4 Others
• 8.2 By Drug Type
  • 8.2.1 Thrombolytics
  • 8.2.2 Antiplatelets
  • 8.2.3 Anticoagulants
  • 8.2.4 Others
• 8.3 By Treatment Type
  • 8.3.1 IV Medication
  • 8.3.2 Endovascular Therapy
  • 8.3.3 Surgical Procedures
    • 8.3.3.1 Mechanical Thrombectomy
    • 8.3.3.2 Carotid Endarterectomy (CEA)
    • 8.3.3.3 Others
• 8.4 By Severity Type
  • 8.4.1 Mild
  • 8.4.2 Moderate
  • 8.4.3 Severe
• 8.5 By Age-Group
  • 8.5.1 Below 20 Years
  • 8.5.2 20 to 50 Years
  • 8.5.3 50 to 70 Years
  • 8.5.4 Older than 70 Years
• 8.6 By End User
  • 8.6.1 Hospitals
  • 8.6.2 Specialty Clinics
  • 8.6.3 Rehabilitation Centers
  • 8.6.4 Others

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size and Forecast
  • 9.1.2 Demand Drivers
  • 9.1.3 Regional Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size and Forecast
  • 9.2.2 Demand Drivers
  • 9.2.3 Regional Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size and Forecast
  • 9.3.2 Demand Drivers
  • 9.3.3 Regional Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size and Forecast
  • 9.4.2 Demand Drivers
  • 9.4.3 Regional Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size and Forecast
  • 9.5.2 Demand Drivers
  • 9.5.3 Regional Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
  • 10.1.1 Market Size
  • 10.1.2 Stroke Epidemiology
  • 10.1.3 Regulatory Framework
  • 10.1.4 Reimbursement Landscape
  • 10.1.5 Key Companies and Products Presence
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States FDA Framework
  • 11.2.1 Drug Approval Pathways
  • 11.2.2 Expedited Programs
• 11.3 European Medicines Agency (EMA)
  • 11.3.1 Centralized Approval Process
  • 11.3.2 Market Access Considerations
• 11.4 Japan PMDA Framework
• 11.5 India CDSCO Framework
• 11.6 China NMPA Framework
• 11.7 Orphan and Special Designation Programs
• 11.8 Pharmacovigilance Requirements
• 11.9 Regulatory Trends Impacting Stroke Therapeutics

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Assessment
• 12.4 Pipeline Competitiveness Assessment
• 12.5 Strategic Initiatives
  • 12.5.1 Collaborations
  • 12.5.2 Licensing Agreements
  • 12.5.3 Acquisitions
  • 12.5.4 Geographic Expansion Strategies
• 12.6 SWOT Analysis
• 12.7 Competitive Positioning Matrix

13. Company Profiles

• 13.1 Genentech
  • 13.1.1 Company Overview
  • 13.1.2 Approved Stroke-Related Products
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline and Clinical Development Activities
  • 13.1.5 Strategic Outlook
• 13.2 Boehringer Ingelheim
  • 13.2.1 Company Overview
  • 13.2.2 Approved Stroke-Related Products
  • 13.2.3 Key Indications
  • 13.2.4 Verified Pipeline Programs
  • 13.2.5 Strategic Outlook
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products Relevant to Stroke Management
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Activities
  • 13.3.5 Strategic Outlook
• 13.4 Novartis AG
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products Relevant to Stroke Prevention
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Activities
  • 13.4.5 Strategic Outlook
• 13.5 Bayer AG
  • 13.5.1 Company Overview
  • 13.5.2 Approved Stroke-Related Products
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Activities
  • 13.5.5 Strategic Outlook
• 13.6 Johnson & Johnson
  • 13.6.1 Company Overview
  • 13.6.2 Approved Stroke-Related Products
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Activities
  • 13.6.5 Strategic Outlook
• 13.7 Daiichi Sankyo
  • 13.7.1 Company Overview
  • 13.7.2 Approved Stroke-Related Products
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Activities
  • 13.7.5 Strategic Outlook
• 13.8 Sanofi
  • 13.8.1 Company Overview
  • 13.8.2 Cardiovascular and Stroke Prevention Portfolio
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Activities
  • 13.8.5 Strategic Outlook
• 13.9 Novo Nordisk
  • 13.9.1 Company Overview
  • 13.9.2 Cardiometabolic Portfolio Relevant to Stroke Risk Reduction
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Activities
  • 13.9.5 Strategic Outlook
• 13.10 AstraZeneca PLC
  • 13.10.1 Company Overview
  • 13.10.2 Approved Stroke-Related Products
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Activities
  • 13.10.5 Strategic Outlook
• 13.11 Merck & Co., Inc.
  • 13.11.1 Company Overview
  • 13.11.2 Cardiovascular Portfolio Assessment
  • 13.11.3 Key Indications
  • 13.11.4 Pipeline Activities
  • 13.11.5 Strategic Outlook
• 13.12 GlaxoSmithKline plc
  • 13.12.1 Company Overview
  • 13.12.2 Cardiovascular Portfolio Assessment
  • 13.12.3 Key Indications
  • 13.12.4 Pipeline Activities
  • 13.12.5 Strategic Outlook
• 13.13 Eli Lilly and Company
  • 13.13.1 Company Overview
  • 13.13.2 Cardiometabolic Portfolio Relevant to Stroke Risk Reduction
  • 13.13.3 Key Indications
  • 13.13.4 Pipeline Activities
  • 13.13.5 Strategic Outlook
• 13.14 AbbVie Inc.
  • 13.14.1 Company Overview
  • 13.14.2 Neuroscience Portfolio Assessment
  • 13.14.3 Key Indications
  • 13.14.4 Pipeline Activities
  • 13.14.5 Strategic Outlook

14. Future Outlook

• 14.1 Market Evolution Through 2035
• 14.2 Emerging Treatment Paradigms
• 14.3 Future Commercial Opportunities
• 14.4 Pipeline Launch Impact Assessment
• 14.5 Precision Medicine Outlook
• 14.6 AI and Digital Health Integration
• 14.7 Analyst Recommendations

15. Methodology

• 15.1 Research Scope and Objectives
• 15.2 Market Definition
• 15.3 Data Collection Methodology
  • 15.3.1 Primary Research
  • 15.3.2 Secondary Research
• 15.4 Market Estimation Methodology
  • 15.4.1 Top-Down Approach
  • 15.4.2 Bottom-Up Approach
  • 15.4.3 Data Triangulation
• 15.5 Forecasting Methodology
• 15.6 Epidemiology Modeling Framework
• 15.7 Pipeline Assessment Framework
• 15.8 Competitive Intelligence Framework
• 15.9 Assumptions and Limitations
• 15.10 Abbreviations and Definitions